A Phase 2 interventional study of Ublituximab in Relapsing Remitting Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-12-21.
Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States — 26 open to participants now, 44 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · United States.
Among the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, this one is the 104th largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2017, is one of 40 in phase 2, and was the 137th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →26 of the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Maryland, Baltimore · Sites in United States
Ages 18–65
SetPoint Medical Corporation · Sites in United States
Ages 22–60
Georgia State University · Sites in United States
Ages 45–89
University of Florida · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 44 · Phase 3 51 · Phase 4 20
First in 1994; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 65 across the 175 interventional studies, 49 across the 53 observational. Of the 164 that completed or were terminated, 82 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 229 have an industry lead sponsor. The 10 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
TG Therapeutics, Inc. has 1 study filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201638Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT04768777University of Alabama at BirminghamBehavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | 2026-12-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
Biological: Ublituximab
Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
Also known as: TG1101
Number of participants with treatment-related events as assessed by CTCAE V4.0
to determine the incidence of adverse events and any abnormal laboratory values
Time frame: 96 weeks on therapy
Evaluate the % of participants with relapses
Time frame: up to 96 Weeks
Plan to share: Undecided — Data will be shared after study completion via publication
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in Nov 2022, 65 months.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 65 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ublituximab
Multiple Sclerosis, Relapsing-Remitting →